MedTrace Logo

A Study of ASN007 in Patients With Advanced Solid Tumors

NCT03415126 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2020-07-09

No results posted yet for this study

Summary

The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.

Conditions

Interventions

DRUG

ASN007: ascending doses

Oral drug for the treatment of advanced solid tumors

DRUG

ASN007 RD

Oral drug for the treatment of advanced solid tumors

Sponsors & Collaborators

  • Asana BioSciences

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Asana BioSciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-19
Primary Completion
2020-06-30
Completion
2020-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03415126 on ClinicalTrials.gov